articleTop 10% cited

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

Clinical Pharmacology & Therapeutics · 2005 · Vol. 78(4) · pp. 412–421

Dagmar Kubitza✉(Bayer (Germany))Michael Becka(Bayer (Germany))Barbara Voith(Bayer (Germany))Michael Zuehlsdorf(Bayer (Germany))Georg Wensing(Bayer (Germany))

View via DOI Publisher page

Abstract

BAY 59--7939 was well tolerated with predictable pharmacodynamics and pharmacokinetics across a wide range of doses in healthy male subjects. BAY 59--7939 was shown to be an effective and specific factor Xa inhibitor.

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis MechanismsPharmacodynamicsPharmacokineticsMedicinePartial thromboplastin timePharmacologyProthrombin timePlaceboCrossover studyInternal medicineCoagulation

MeSH terms

RivaroxabanAdultDose-Response Relationship, DrugFibrinolytic AgentsHalf-LifeHumansMaleMetabolic Clearance RateMiddle AgedMorpholinesThiophenesSingle-Blind MethodCross-Over StudiesArea Under CurveFactor Xa Inhibitors

Citations

652

FWCI

10.10

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

Cited by

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation